EGFR and non-small cell lung carcinoma: With the development of next-generation sequencing (NGS), more and more co-mutations in advanced EGFR mutated-NSCLC patients were found, and these co-mutations might be one of the mechanisms of primary drug resistance, among which TP53 mutations were the most frequent co-mutations, accounting for about 17.3-72.5% (19, 23).